Brusabhanu Nayak 🇮🇳
@brusabhanu1
Professor Uro-oncolgy, AIIMS, New Delhi
Retweet or Like is not endorsement. Views are personal.
ID: 502699661
25-02-2012 08:34:29
7,7K Tweet
126 Takipçi
753 Takip Edilen
Subgroup findings from CREST trial in high-risk #BladderCancer. Gary Steinberg Rush University System for Health joins Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center in this discussion on UroToday > bit.ly/3KSGZQE
Molecular classifier studies to identify aggressive subgroup in low-grade #Bladder tumors. Ewan Gibb Vancouver Prostate Centre joins Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center to discuss the development of a molecular classifier for identifying aggressive TA low-grade #BladderCancer tumors. #WatchNow >
Thanks Atul Batra for organizing wonderful uro oncology meeting AIIMS, New Delhi 🇮🇳 Sumanta K. Pal, MD, FASCO Neeraj Agarwal, MD, FASCO Petros Grivas Saphalta
Thanks my friend Ashish M. Kamat, MD, MBBS it is my pleasure/honour to be in amazing India with esteemed colleagues, bright minds! Hospitality, social agenda, scientific content fantastic! AIIMS, New Delhi 🇮🇳 Neeraj Agarwal, MD, FASCO Atul Batra Aparna Sharma Sumanta K. Pal, MD, FASCO Dr Amol Akhade Rahul Banerjee, MD, FACP Fred Hutch Cancer Center
🆕adjuvant combo for #RCC : LITESPARK-022 #GU26 DFS: HR: 0.72‼️ OS: inmature data..... but comparator arm was THE most effective active treatment available. Toni Choueiri, MD Tom Powles Maite Bourlon ASCO